Fate Therapeutics completed $30M Series B Financing
Summary
Fate Therapeutics, Inc., a La Jolla, CA-based developer of a Stem Cell Modulator, FT1050, to enhance hematopoietic stem cell (HSC) proliferation and homing, has completed a $30m Series B financing.The round was led by OVP Venture Partners with participation from OVP Venture Partners Astellas Venture Management, Genzyme Ventures and a third undisclosed corporate investor.The three co-leaders of the Company’s Series A financing, ARCH Venture Partners, Polaris Venture Partners and Venrock, also participated in the latest round of financing.In conjunction with the funding, Carl Weissman, managing director at OVP Venture Partners, joined the Company’s board of directors.
Funding
Review available funding amount, funding date, investors, and linked company information related to Fate Therapeutics completed $30M Series B Financing in the interactive ISVWorld profile.